A breakthrough in cancer research has revealed crucial insights into the aggressive nature of pancreatic cancer, providing renewed hope for developing effective treatments. An international team of scientists from the UK and the US has uncovered how pancreatic cancer disables vital molecules in a key gene, enabling the disease to grow and spread rapidly.
This discovery could potentially revolutionize the approach to treating one of the deadliest forms of cancer.
Pancreatic cancer, the 12th most common cancer globally, affects over half a million people each year and has the worst survival rates among common cancers. More than half of those diagnosed with pancreatic cancer die within three months, often due to late-stage detection when treatment options are severely limited.
The disease’s aggressive nature and poor prognosis have long puzzled experts, but the recent findings shed new light on the underlying mechanisms of its rapid progression.
Researchers analyzed both healthy and cancerous pancreatic tissue samples to understand the molecular changes driving the disease. They discovered that pancreatic cancer initiates a process called DNA methylation, which inactivates molecules in the HNF4A gene.
This gene is essential for the proper functioning of many body organs, and its suppression by cancer cells allows tumours to grow unchecked. The study indicates that the loss of HNF4A is directly linked to the development and aggressiveness of pancreatic cancer, correlating with poor patient survival rates.
This research involved a collaboration between Nottingham Trent University, the University of Nottingham, Stanford University, the University of California, and Cedars-Sinai Medical Center in Los Angeles. The project was funded by Pancreatic Cancer UK, which underscores the urgent need for more effective and less invasive treatment options for this devastating disease. Currently, 80% of pancreatic cancer cases are diagnosed only after the cancer has spread and is no longer operable.
Understanding the role of DNA methylation in pancreatic cancer progression opens new avenues for therapeutic interventions. By targeting the mechanisms that allow cancer cells to suppress the HNF4A gene, scientists hope to develop treatments that can halt or even reverse the disease's progression.